Table 1. Baseline characteristics of the study patients (n = 327).

		n	(%)	Median (range)
FGFR2 qPCR value	gene copy number ≥8	16	4.9	2.64 (0.73–504.04)
Gender	Male	226	69.1
Age	≥65 years	93	35.9	58 (23–85)
ECOG PS	0 or 1	228	88.1
Borrmann type	I	17	5.2
	II	71	21.7
	III	178	54.4
	IV	50	15.3
	Not available	11	3.4
Histology	WD/MD	117	35.8
	PD/SRC/mucinous	204	62.4
	Others	6	1.8
HER2/neua	Positive	19	5.8
	Negative	103	31.5
	Not tested	205	62.8
No gastrectomy		211	64.5
Disease status	Initially metastatic	215	68.8
	Recurred	99	30.3
	Locally advanced	13	0.9
Metastatic organ	Peritoneum	157	48.0
	Liver	95	29.1
	Lung	20	6.1
	Intraabdominal distant LN	154	47.1
	Extra-abdominal distant LN	31	9.5
	Bone	27	8.3
Hemoglobinb, c	≤lower normal limit	223	68.3	11.7 (6.7–17.4)
White blood cellc	≥10000/mm3	47	14.4	6850 (2200–48700)
Plateletc	≤150×103/mm3	38	11.9	264 (14–646) × 103
Albumind	<3.3 g/dL	104	31.8	3.6 (1.7–5.3)
Alkaline phosphatasec	>120 IU/L	71	21.7	79.5 (29–1294)
Total bilirubin c	>1.2 mg/dL	29	8.9	0.6 (0.2–6)
Risk groups c,e	Good (0–1)	154	47.1
	Moderate (2–3)	112	34.3
	Poor (≥4)	52	15.9

Abbreviations: qPCR, quantitative polymerase chain reaction; ECOG PS, Eastern Cooperative Oncology Group Performance Status; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; SRC, signet ring cell carcinoma; LN, lymph node

^aHER2/neu-positive was defined as a positive score of ≥2 on immunohistochemistry and/or positive results from silver in situ hybridization

^bHemoglobin ≤12 g/dL for women and ≤13 g/dL for men.

^cInitial complete blood count, alkaline phosphatase level, bilirubin level, and scores of the Asan Medical Center prognostic model were not available for 9 patients (2.8%).

^dAlbumin levels were not available in 11 patients (3.4%)

^eAccording to the Asan Medical Center prognostic model